DRUGS & THERAPY PERSPECTIVES

Scope & Guideline

Catalyzing Change in the World of Pharmacology and Therapy

Introduction

Explore the comprehensive scope of DRUGS & THERAPY PERSPECTIVES through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore DRUGS & THERAPY PERSPECTIVES in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1172-0360
PublisherSPRINGERNATURE
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1993 to 2024
AbbreviationDRUGS THER PERSPECT / Drugs. Ther. Perspect.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

The journal 'DRUGS & THERAPY PERSPECTIVES' focuses on providing comprehensive insights into the use and management of pharmacological therapies across a variety of medical conditions. Its primary aim is to enhance the understanding of drug therapies, their clinical implications, and the overall therapeutic landscape.
  1. Pharmacotherapy Profiles:
    The journal frequently publishes detailed profiles of existing and emerging pharmacotherapies, highlighting their efficacy, safety, and clinical applications across various diseases.
  2. Clinical Decision-Making:
    Research often emphasizes the role of clinical decision-making in pharmacotherapy, particularly in complex cases such as managing multiple comorbidities in older adults.
  3. Pharmacovigilance and Safety:
    A significant focus is placed on pharmacovigilance, with studies examining adverse drug reactions, medication errors, and the impact of clinical pharmacy services on patient safety.
  4. Emerging Therapies and Innovations:
    The journal covers new and innovative treatments, providing insights into their potential benefits and limitations, which is crucial for clinicians looking to implement cutting-edge therapies.
  5. Healthcare Policy and Access to Medicines:
    Research also addresses healthcare policy issues, including access to medications and the implications of health technology assessments on clinical practice.
Recent publications in 'DRUGS & THERAPY PERSPECTIVES' reveal a shift towards several trending and emerging themes that reflect current challenges and innovations in the field of pharmacotherapy. This section outlines these trends.
  1. Personalized Medicine:
    An increasing number of articles emphasize the importance of personalized medicine, tailoring pharmacotherapy to individual patient needs, particularly in complex cases or chronic conditions.
  2. Management of Chronic Conditions:
    There is a growing focus on the management of chronic conditions such as diabetes, hypertension, and mental health disorders, reflecting the need for more effective long-term treatment strategies.
  3. Pharmacogenomics:
    Research exploring pharmacogenomic approaches to optimizing drug therapy based on genetic profiles is on the rise, indicating a shift towards more precise prescribing practices.
  4. Telehealth and Digital Health Solutions:
    With the rise of telehealth, the journal is increasingly addressing the role of digital health solutions in managing therapy adherence and patient engagement.
  5. Comprehensive Safety Evaluations:
    There is a trend towards more comprehensive evaluations of drug safety, including monitoring long-term effects and interactions, especially in vulnerable populations such as the elderly.

Declining or Waning

While 'DRUGS & THERAPY PERSPECTIVES' continues to explore a broad range of therapeutic areas, certain themes appear to be declining in prominence over recent years. This section highlights these waning scopes.
  1. Traditional Pharmacotherapy:
    There has been a noticeable decrease in articles focusing solely on traditional pharmacotherapy approaches, as the journal shifts towards more innovative and personalized treatment strategies.
  2. Generalized Guidelines for Drug Use:
    Publications that offer generalized treatment guidelines without specific contexts or patient populations are becoming less frequent, reflecting a trend towards more individualized and nuanced approaches to therapy.
  3. Focus on Older Pharmacological Agents:
    Research pertaining to older pharmacological agents is diminishing, possibly as newer therapeutics gain traction and as the focus shifts towards novel treatments and their comparative efficacy.
  4. Single-Agent Therapy Studies:
    There is a waning interest in studies that examine the efficacy of single-agent therapies, with more emphasis now placed on combination therapies and multidisciplinary treatment approaches.

Similar Journals

ANNALS OF PHARMACOTHERAPY

Advancing the Frontiers of Pharmacotherapy
Publisher: SAGE PUBLICATIONS INCISSN: 1060-0280Frequency: 12 issues/year

ANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.

JOURNAL OF PHARMACY TECHNOLOGY

Exploring the forefront of pharmacy technology and application.
Publisher: SAGE PUBLICATIONS INCISSN: 8755-1225Frequency: 6 issues/year

JOURNAL OF PHARMACY TECHNOLOGY is a premier publication in the field of Pharmaceutical Science, established in 1989 and published by SAGE PUBLICATIONS INC. This journal serves as an essential resource for professionals, researchers, and students dedicated to the advancements in pharmacy technology and the application of innovative solutions in pharmaceutical practices. With an ISSN of 8755-1225 and an E-ISSN of 1549-4810, the journal provides a rigorous peer-reviewed platform for disseminating cutting-edge research and case studies. As of 2023, it is ranked Q3 in the Scopus categories of Pharmacology, Toxicology, and Pharmaceutics, highlighting its relevance in the field. Although it currently does not offer an Open Access option, JOURNAL OF PHARMACY TECHNOLOGY aims to remain a critical avenue for scholarly communication and knowledge dissemination among practitioners in the pharmaceutical sector, ensuring they stay informed of the latest trends and findings that impact their work.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Charting new territories in ocular pharmacology and therapeutics.
Publisher: MARY ANN LIEBERT, INCISSN: 1080-7683Frequency: 10 issues/year

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, published by Mary Ann Liebert, Inc, stands at the forefront of research in the realms of ophthalmology and pharmacology. Established in 1985 and converging until 2024, this esteemed journal is dedicated to advancing the understanding of ocular pharmacology, drug therapies, and therapeutic approaches in the treatment of eye diseases. With an impressive impact factor and categorized in the Q2 quartile for both Ophthalmology and Medical Pharmacology, it showcases pivotal research in the field, reflecting its rank of #31 among 137 in Ophthalmology and #109 among 272 in Medical Pharmacology per Scopus metrics. Although it follows a subscription-based model, the journal provides critical insights and empirical studies that foster innovation and collaboration for researchers, professionals, and students alike in the pursuit of improving ocular health.

Australian Prescriber

Fostering Innovation in Medical Prescriptions.
Publisher: Therapeutic Guidelines LtdISSN: 0312-8008Frequency: 6 issues/year

Australian Prescriber is a distinguished open-access journal published by Therapeutic Guidelines Ltd, aiming to advance the field of pharmacology and medical prescriptions. Since its inception in 1994, this journal has been dedicated to disseminating essential findings and insights related to therapeutic guidelines and pharmaceutical care, making it an invaluable resource for healthcare professionals and researchers alike. With an ISSN of 0312-8008 and an E-ISSN of 1839-3942, it caters to an audience that values evidence-based medicine, empowering practitioners with knowledge to enhance clinical practice. The journal currently holds a Q2 ranking in the Pharmacology (medical) category and is recognized in the 51st percentile among its peers, reflecting its significant contributions to the medical field. Available from 1995 to 2024, this journal not only serves as an academic platform but also a critical discussion forum for professionals keen on improving pharmacological practices in Australia and beyond.

EXPERT OPINION ON INVESTIGATIONAL DRUGS

Driving Progress in Investigational Medicine
Publisher: TAYLOR & FRANCIS LTDISSN: 1354-3784Frequency: 12 issues/year

Expert Opinion on Investigational Drugs, published by Taylor & Francis Ltd, is a premier journal dedicated to the dissemination of high-quality, peer-reviewed research in the fields of pharmacology and medicine. As an integral part of the scientific community since its inception in 1994, this journal has established itself as a leading source of insightful analysis and expert commentary on emerging drug therapies, providing invaluable resources for researchers, clinicians, and healthcare professionals. With an impressive impact factor and ranking in the top quartile across multiple pharmacological categories, it remains a vital platform for discussing innovative drug developments and their clinical applications. Though it operates on a subscription basis, Expert Opinion on Investigational Drugs is crucial for anyone involved in pharmacological research and the drug development process, positioning itself at the forefront of medical advancements and offering critical insights into the rapid evolution of investigational therapies.

DRUGS

Unveiling Breakthroughs in Drug Development
Publisher: ADIS INT LTDISSN: 0012-6667Frequency: 18 issues/year

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.

Expert Opinion On Drug Safety

Elevating Standards in Pharmacological Research
Publisher: TAYLOR & FRANCIS LTDISSN: 1474-0338Frequency: 6 issues/year

Expert Opinion on Drug Safety is a prestigious academic journal dedicated to advancing knowledge in the fields of drug safety and pharmacology. Published by Taylor & Francis Ltd, this journal serves as an essential resource for researchers and professionals seeking to explore the complexities of drug interactions, adverse effects, and risk management. With an impressive impact factor and recognized as a Q1 journal in both the Medicine (Miscellaneous) and Pharmacology (Medical) categories, it ranks favorably at #78 out of 272 in Scopus, placing it in the 71st percentile among its peers. Operating under a rigorous peer-review process, the journal publishes original research, expert reviews, and opinion pieces that contribute to a deeper understanding of drug safety practices. While not an open access journal, it remains a vital platform for disseminating pivotal findings and fostering scholarly dialogue, ensuring that critical insights reach a global audience. With continuous publication from 2002 to 2024, Expert Opinion on Drug Safety is a key reference for anyone involved in pharmaceutical research, healthcare practice, or drug regulation.

CARDIOVASCULAR DRUGS AND THERAPY

Transforming cardiovascular health with rigorous research.
Publisher: SPRINGERISSN: 0920-3206Frequency: 6 issues/year

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

International Journal of Clinical Pharmacy

Advancing Clinical Pharmacy Knowledge for Global Impact
Publisher: SPRINGERISSN: 2210-7703Frequency: 6 issues/year

The International Journal of Clinical Pharmacy, published by Springer, serves as a pivotal platform for advancing research in the fields of Pharmaceutical Science and Pharmacology. This esteemed journal, recognized for its significant impact with an impressive Q1 ranking in Pharmacy and multiple Q2 designations, provides a dedicated space for scholars and practitioners to share innovative findings and methodologies that enhance clinical pharmacy practices. With an international reach and publication spanning from 2011 to 2024, the journal aims to facilitate knowledge exchange among researchers, professionals, and students, ultimately contributing to improved therapeutic outcomes. As an open-access journal, it promotes widespread dissemination of vital research, ensuring that cutting-edge clinical pharmacy knowledge is accessible to all stakeholders in the healthcare continuum.

EXPERT OPINION ON PHARMACOTHERAPY

Navigating the Evolving Landscape of Pharmacotherapy
Publisher: TAYLOR & FRANCIS LTDISSN: 1465-6566Frequency: 12 issues/year

EXPERT OPINION ON PHARMACOTHERAPY, published by Taylor & Francis Ltd, stands as a vital resource in the fields of medicine and pharmacology, consistently recognized for its significant contributions to both disciplines. With an impressive impact factor, this journal ranks in the second quartile (Q2) across several key categories, including Medicine (miscellaneous), Pharmacology, and Medical Pharmacology, underscoring its influence within the academic community. Since its inception in 1999, the journal has provided a platform for peer-reviewed articles that critically evaluate emerging therapies and innovative pharmacological approaches, making it essential reading for researchers, healthcare professionals, and students alike. Although it operates under a subscription model, its comprehensive coverage of pharmacotherapeutic developments ensures that it remains a cornerstone for those seeking new insights and expert analyses in the rapidly evolving landscape of drug therapy.